# US 2020/0390820 A1 · Isolation, cultivation and uses of stem/progenitor cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390820 A1
- Document ID: US20200390820A1
- Status: Published application
- Kind: A1
- Application number: 17/006,257
- Filed: 2020-08-28
- Published: 2020-12-17
- Earliest claimed: 2004-08-16
- Assignees: Cellresearch Corporation Pte. Ltd.
- Applicants: Cellresearch Corporation Pte. Ltd.
- Inventors: Toan Thang PHAN; Ivor Jiun LIM
- Web page: https://patentgrep.com/patent/US20200390820A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 35/36: Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells (islets of Langerhans A61K35/39)
- A61K 35/51: Umbilical cord; Umbilical cord blood; Umbilical stem cells
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 5/24: of the sex hormones
- A61P 5/38: of the suprarenal hormones
- A61P 5/48: of the pancreatic hormones
- A61P 7/06: Antianaemics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/16: Emollients or protectives, e.g. against radiation
- A61P 17/18: Antioxidants, e.g. antiradicals (preparations for protection against sunlight A61Q17/00)
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- C12N 5/0603: {Embryonic cells (production of embryos, nuclear transfer A01K67/027); Embryoid bodies}
- C12N 5/0605: {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- C12N 5/0606: {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696)}
- C12N 5/0629: {Keratinocytes; Whole skin}
- C12N 5/063: {Kereatinocyte stem cells; Keratinocyte progenitors}
- C12N 5/0668: {Mesenchymal stem cells from other natural sources}
- C12N 2506/025: from extra-embryonic cells, e.g. trophoblast, placenta
- C12N 2506/1392: from mesenchymal stem cells from other natural sources
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a method of cultivating mammalian cells. This method comprises cultivating the mammalian cells on a feeder layer, wherein the feeder layer comprises a stem/progenitor cell population isolated from the amniotic membrane of the umbilical cord

## Claims

### Claim 1

A method of cultivating mammalian cells comprising cultivating said mammalian cells on a feeder layer, wherein the feeder layer comprises a stem/progenitor cell population isolated from the amniotic membrane of the umbilical cord.

### Claim 2 (depends on 1)

The method of claim 1, wherein the stem/progenitor cell population isolated from the amniotic membrane of the umbilical cord is an epithelial or mesenchymal stem/progenitor cell population that express the following genes: POU5f1, Bmi-1, leukemia inhibitory factor (LIF), and secrete Activin A and Follistatin.

### Claim 3 (depends on 2)

The method of claim 2, wherein the epithelial or mesenchymal stem/progenitor cell population express the following growth factors: connective tissue growth factor (CTGF), vascular endothelial growth factor (VEGF), placenta-like growth factor PLGF, STAT3, stem cell factor (SCF), Hepatoma-derived Growth Factor (HDGF), Fibroblast Growth Factor-2 (FGF-2), Platelet-derived Growth Factor (PDGF), alpha-Smooth Muscle Actin (α-SMA), Fibronectin, Decorin, and Syndecan-1,2,3,4.

### Claim 4 (depends on 1)

The method of claim 1, wherein the stem/progenitor cell population is isolated from the amniotic membrane of the umbilical cord by a method comprising:
(a) separating the amniotic membrane from the other components of the umbilical cord in vitro to obtain amniotic membrane tissue;
(b) culturing the amniotic membrane tissue obtained in step (a) under conditions allowing cell proliferation; and
(c) isolating the stem/progenitor cells, and wherein the stem/progenitor cells are epithelial or mesenchymal stem/progenitor cells.

### Claim 5 (depends on 1)

The method of claim 1, wherein the feeder layer essentially consists of a stem/progenitor cell population isolated from the amniotic membrane of the umbilical cord.

### Claim 6 (depends on 1)

The method of claim 1, wherein the stem/progenitor cell population isolated from the amniotic membrane of the umbilical cord is a human stem/progenitor cell population.

### Claim 7 (depends on 1)

The method of claim 1, wherein the mammalian cells are stem cells.

### Claim 8 (depends on 7)

The method of claim 7, wherein the stem cells are embryonic stem cells.

### Claim 9 (depends on 1)

The method of claim 1, wherein the mammalian cells are cultured under serum free conditions.
